Fairvalue-Calculator Fairvalue-Calculator
EN DE

20/20 Biolabs, Inc (AIDX) Fair Value & Analysis

Healthcare · US · Market cap $6.1M

Price$0.6118
Fair Value$0.4800
Upside-21.5%
Quality80/100
Evidence: Low Range $0.3600 – $0.6000

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

20/20 Biolabs, Inc (AIDX) currently trades at $0.6118, while our model-based Fair Value estimate is $0.4800 — implying the stock looks roughly 21.5% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is 20/20 Biolabs, Inc (AIDX) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.4800 versus a price of $0.6118 — about −22% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AIDX?
Our 21-model fair value for 20/20 Biolabs, Inc is $0.4800 (as of Jun 23, 2026), built from audited fundamentals. The current price is $0.6118.
What is the quality score of AIDX?
20/20 Biolabs, Inc has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.